Allergy and Immunology · Mount Clemens, MI
NPI
1710950951
Since 2006
Specialty
Allergy and Immunology
Code 207K00000X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
1030 Harrington St Ste 301
Mount Clemens, MI, 48043
Phone (586) 961-6060
Groups this clinician bills Medicare through
Medicare paid, 2024
$220K
16,312 services
Medicare patients, 2024
350
Average age 70
Drug cost, 2024
$3.0M
3,270 prescriptions
Company payments, 2025
$146K
From 26 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Pulin P Patel was code 95165 (treatment - miscellaneous), 4,821 times for 122 patients. In total Pulin P Patel billed 16,312 services in 24 codes, and Medicare paid $220K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-09-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 95165 Treatment - Miscellaneous | Office | 4,821 | 122 | $11.03 | $53K |
| 95004 Test - Miscellaneous | Office | 4,312 | 84 | $2.98 | $13K |
| 95117 Treatment - Miscellaneous | Office | 2,584 | 130 | $8.83 | $23K |
| 95024 Test - Miscellaneous | Office | 1,466 | 83 | $6.36 | $9,323 |
| 94060 Pulmonary Function Testing | Office | 460 | 287 | $28.94 | $13K |
| 95012 Pulmonary | Office | 414 | 268 | $14.14 | $5,853 |
| 96401 Chemotherapy Administration | Office | 298 | 17 | $52.12 | $16K |
| 99213 Office E&M - Established | Office | 277 | 193 | $66.04 | $18K |
| 99214 Office E&M - Established | Office | 181 | 127 | $91.67 | $17K |
| 99205 Office E&M - New | Office | 90 | 90 | $160.86 | $14K |
| 99223 Hospital E&M - Initial | Facility | 26 | 23 | $130.23 | $3,386 |
By year: 2022 $268K for 20,566 services; 2023 $231K for 17,012 services; 2024 $220K for 16,312 services.
Medicare prescription drug claims, 2024
In 2024, the drug Pulin P Patel prescribed most often to Medicare patients was Montelukast Sodium, with 772 prescriptions and refills. In total Pulin P Patel wrote 3,270 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Montelukast Sodium Generic | 772 | 1,755 | 233 | $10K |
| Fluticasone Propionate Generic | 208 | 392 | 72 | $5,002 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 203 | 262 | 55 | $162K |
| Azelastine Hcl Generic | 195 | 275 | 81 | $5,171 |
| Dupixent Syringe Dupilumab | 148 | 157 | 22 | $595K |
| Xolair Omalizumab | 145 | 145 | 14 | $478K |
| Levocetirizine Dihydrochloride Generic | 141 | 299 | 45 | $2,143 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 97 | 142 | 29 | $18K |
| Ipratropium Bromide Generic | 92 | 133 | 35 | $3,223 |
| Spiriva Respimat Tiotropium Bromide | 91 | 123 | 22 | $61K |
| Gamunex-C Immune Globul G/Gly/Iga Avg 46 | 76 | 76 | Under 11 | $249K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 76 | 81 | 63 | $2,265 |
| Breo Ellipta Fluticasone/Vilanterol | 72 | 84 | 15 | $33K |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 66 | 108 | 27 | $22K |
| Advair Hfa Fluticasone Propion/Salmeterol | 61 | 75 | 20 | $23K |
Brand drugs: 1,429 claims; generic drugs: 1,841 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Pulin P Patel $146K ($146K in general payments such as food, travel and fees) from 26 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $59K.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 99 | $59K |
| ARS Pharmaceuticals Operations, Inc. SPRY | 53 | $31K |
| Genzyme Corporation SNY | 45 | $30K |
| Pharming Healthcare, Inc. | 8 | $9,791 |
| Novartis Pharmaceuticals Corporation NVS | 19 | $6,502 |
| Regeneron Healthcare Solutions, Inc. REGN | 16 | $4,490 |
| Sanofi US Services Inc. SNY | 3 | $1,528 |
| GlaxoSmithKline, LLC. GSK | 29 | $717 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 15 | $414 |
| Amgen Inc. AMGN | 20 | $379 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.